GXI Stock Analysis: Gerresheimer | XETRA
Medical Instruments & Supplies | XETRA, Germany | Market Cap: 1.002m EUR | 12M Return: -6% | DE000A0LD6E6 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.73M
Qual. Beats: -3
Rev. Trend: 93.4%
Qual. Beats: -1
Warnings
Tailwinds
No distinct edge detected
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Gerresheimer AG is a German-headquartered provider of drug containment and delivery solutions, operating internationally through three divisions: Plastics & Devices, Primary Packaging Glass, and Advanced Technologies. Its product portfolio spans prefillable syringes, vials, ampoules, glass cartridges, bottles, and containers, alongside drug delivery devices such as inhalers, auto-injectors, and pen injectors. Beyond pharmaceutical packaging, the company supplies diagnostic and medical devices (e.g., point-of-care tests, lancing devices, infusion sets), as well as cosmetic packaging including moulded glass flacons and jars.
The company serves a diverse B2B customer base across the pharma, biotech, medical technology, diagnostics, cosmetics, and food and beverage industries, distributing through pharmacy chains, supermarkets, and wholesalers. Founded in 1864 and headquartered in Düsseldorf, Gerresheimer operates as a specialty supplier rather than a direct-to-consumer brand, with its revenue tied closely to pharmaceutical packaging demand and drug development pipelines. As a Health Care Equipment company, it sits within a niche of the healthcare value chain focused on containment and delivery rather than therapeutic production itself.
- High-margin biologics syringes drive Plastics & Devices growth
- German energy costs pressure Primary Packaging Glass margins
- Bormioli integration expands pharma glass packaging footprint
| Net Income: -400.6m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 19.84 > 1.0 |
| NWC/Revenue: 4.36% < 20% (prev -35.81%; Δ 40.17% < -1%) |
| CFO/TA 0.06 > 3% & CFO 261.6m > Net Income -400.6m |
| Net Debt (2.14b) to EBITDA (238.1m): 9.00 < 3 |
| Current Ratio: 1.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (34.5m) vs 12m ago 0.0% < -2% |
| Gross Margin: 15.28% > 18% (prev 28.95%; Δ -13.67% > 0.5%) |
| Asset Turnover: 49.51% > 50% (prev 43.17%; Δ 6.34% > 0%) |
| Interest Coverage Ratio: -3.31 > 6 (EBIT TTM -272.9m / Interest Expense TTM 82.3m) |
| A: 0.02 (Total Current Assets 1.53b - Total Current Liabilities 1.43b) / Total Assets 4.35b |
| B: 0.18 (Retained Earnings 799.2m / Total Assets 4.35b) |
| C: -0.06 (EBIT TTM -272.9m / Avg Total Assets 4.60b) |
| D: 0.28 (Book Value of Equity 956.5m / Total Liabilities 3.37b) |
| Altman-Z'' = 0.65 = B |
| DSRI: 0.70 (Receivables 254.5m/335.7m, Revenue 2.28b/2.09b) |
| GMI: 1.89 (GM 28.95% / 15.28%) |
| AQI: 0.64 (AQ_t 0.24 / AQ_t-1 0.38) |
| SGI: 1.09 (Revenue 2.28b / 2.09b) |
| TATA: -0.15 (NI -400.6m - CFO 261.6m) / TA 4.35b) |
| Beneish M = -2.63 (Cap -4..+1) = A |
As of October 10, 2026, the stock is trading at EUR 28.66 with a total of 92,668 shares traded. Over the past week, the price has changed by +4.14%, over one month by -1.71%, over three months by -1.44% and over the past year by -6.01%.
Current recommended Stop Loss: 27.30 (which is 4.7% or 1.2 ATR below the current price).
Gerresheimer has no consensus analysts rating.
P/E Forward = 9.9108
P/S = 0.4323
P/B = 0.8523
P/EG = 1.2325
Revenue TTM = 2.28b EUR
EBIT TTM = -272.9m EUR
EBITDA TTM = 238.1m EUR
Long Term Debt = 1.52b EUR (from longTermDebt, last fiscal year)
Short Term Debt = 618.2m EUR (from shortTermDebt, last quarter)
Debt = 2.31b EUR (from shortLongTermDebtTotal, last quarter) + Leases 104.3m
Net Debt = 2.14b EUR (calculated: Debt 2.31b - CCE 167.6m)
Enterprise Value = 3.14b EUR (1.00b + Debt 2.31b - CCE 167.6m)
Interest Coverage Ratio = -3.31 (Ebit TTM -272.9m / Interest Expense TTM 82.3m)
EV/FCF = 8.51x (Enterprise Value 3.14b / FCF TTM 369.5m)
FCF Yield = 11.75% (FCF TTM 369.5m / Enterprise Value 3.14b)
FCF Margin = 16.23% (FCF TTM 369.5m / Revenue TTM 2.28b)
Net Margin = -17.60% (Net Income TTM -400.6m / Revenue TTM 2.28b)
Gross Margin = 15.28% ((Revenue TTM 2.28b - Cost of Revenue TTM 1.93b) / Revenue TTM)
Gross Margin QoQ = 10.37% (prev 0.28%)
Tobins Q-Ratio = 0.72 (Enterprise Value 3.14b / Total Assets 4.35b)
Interest Expense / Debt = 3.56% (Interest Expense 82.3m / Debt 2.31b)
Taxrate = 25.0% (non-US conservative default 25%)
NOPAT = -204.7m (EBIT -272.9m * (1 - 25.00%)) [loss with tax shield]
Current Ratio = 1.07 (Total Current Assets 1.53b / Total Current Liabilities 1.43b)
Debt / Equity = 2.41 (Debt 2.31b / totalStockholderEquity, last quarter 956.5m)
Debt / EBITDA = 9.00 (Net Debt 2.14b / EBITDA 238.1m)
Debt / FCF = 5.80 (Net Debt 2.14b / FCF TTM 369.5m)
Total Stockholder Equity = 1.22b (last 4 quarters mean from totalStockholderEquity)
RoA = -8.72% (Net Income -400.6m / Total Assets 4.35b)
RoE = -32.84% (Net Income TTM -400.6m / Total Stockholder Equity 1.22b)
RoCE = -9.96% (EBIT -272.9m / Capital Employed (Equity 1.22b + L.T.Debt 1.52b))
RoIC = -5.97% (negative operating profit) (NOPAT -204.7m / Invested Capital 3.43b)
WACC = 4.35% (E(1.00b)/V(3.31b) * Re(8.21%) + D(2.31b)/V(3.31b) * Rd(3.56%) * (1-Tc(0.25)))
Discount Rate = 8.21% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 0.0 | Cagr: 0.0%
[DCF] Terminal Value 75.44% ; FCFF base≈369.5m ; Y1≈371.0m ; Y5≈393.0m
[DCF] Fair Price = 115.0 (EV 6.11b - Net Debt 2.14b = Equity 3.97b / Shares 34.5m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -1.45 | # QB: -3
Revenue Correlation: 93.44 | Revenue CAGR: 6.58% | SUE: -1.82 | # QB: -1
EPS current Year (2026-11-30): EPS=1.78 | Chg30d=-19.33% | Revisions=-17% | GrowthEPS=+195.1% | GrowthRev=+1.2%
EPS next Year (2027-11-30): EPS=1.61 | Chg30d=-9.26% | Revisions=-50% | GrowthEPS=+516.9% | GrowthRev=+2.8%
[Analyst] Revisions Ratio: -44% (up=1, down=5)